23 February 2016 - The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. PTC first learned of the Refuse to File decision via this letter and is reviewing its content to determine the appropriate next steps.

For more details, go to: http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=956451